The AGENT study showed neither any clinical or commercial value

“Given the AGENT study results’ low clinical and business value for Isofol, we began work during the quarter to terminate the study. This must be carried out in accordance with applicable ethical aspects and regulatory requirements. This work is extensive and will therefore require both time and resources throughout autumn 2022 and the beginning of 2023. We also took active measures to reduce costs and secure the company’s financial position, which has been our utmost priority along with finding any positive outcomes in the study data and terminating the study”, says CEO Ulf Jungnelius.